Related Experiment Video
Updated: Jun 9, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation
Christopher J Mortko1, Agam R Sheth, Narayan Variankaval
1Basic Pharmaceutical Sciences, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, USA. christopher_mortko@merck.com
Abstract:
(1S,5R)-2-{[(4S)-azepan-4-ylamino]carbonyl}-7-oxo-2,6-diazabicyclo[3.2.0] heptane-6-sulfonic acid (Compound 1) is a β-lactamase inhibitor for intravenous administration. The objective of this preformulation study was to determine the most appropriate form of the API for development. Compound 1 can exist as an amorphous solid and four distinct crystalline phases A, B, C, and D in the solid state. Slurry experiments along with analysis of physicochemical properties were used to construct a phase diagram and select the most suitable form of the API for development. In aqueous formulations, the dihydrate form of the API was predominant and, due to the more favorable solubility and dissolution profile required for preclinical and clinical studies, a metastable form of the API was selected, and the risks associated with developing this form were evaluated.
More Related Videos
07:20Discovery and Synthesis Optimization of Isoreticular Al(III) Phosphonate-Based Metal-Organic Framework Compounds Using High-Throughput Methods
Published on: October 6, 2023
09:44Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery
Published on: September 26, 2025
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules